Corline Biomedical AB (CLBIO) — Capital Reinvestment Ratio
Latest as of March 2024:
0.80x
Corline Biomedical AB (CLBIO) has a Capital Reinvestment Ratio of 0.80x as of March 2024, meaning it reinvests 1% of its operating cash flow (Skr2.30 Million) in capital expenditures (Skr1.83 Million). See Corline Biomedical AB (CLBIO) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.80x
Capex / Operating Cash Flow
Operating Cash Flow
Skr2.30 Million
SEK
Capital Expenditures
Skr1.83 Million
SEK
Data as of
Mar 2024
Most recent filing
Corline Biomedical AB Capital Reinvestment Ratio (2023–2023)
This chart tracks Corline Biomedical AB's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Corline Biomedical AB (2023–2023)
Year-by-year Capital Reinvestment Ratio for Corline Biomedical AB from 2023 to 2023. For live market cap and broader valuation context, see market value of Corline Biomedical AB.
| Year | Reinvestment Ratio | Operating CF (SEK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 11.99x | Skr886.00K | Skr10.62 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow